Dermata Therapeutics, INC Schedule 13G passive stakes

Dermata Therapeutics, Inc. has filed a Schedule 13G detailing beneficial ownership of common stock by Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC.

Bigger Capital Fund LP and associated entities have filed an amendment to their Schedule 13G, reporting a reduction in their beneficial ownership of Dermata Therapeutics, Inc. to below 5%.

Michael Bigger and affiliated entities, Bigger Capital and District 2 Capital, have disclosed a combined beneficial ownership of 9.89% in Dermata Therapeutics, Inc.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 5.5% beneficial ownership stake in Dermata Therapeutics, Inc.

A group of investment entities and an individual, led by Michael Bigger, have disclosed beneficial ownership of 7.43% of Dermata Therapeutics, Inc.'s common stock.

Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Dermata Therapeutics, Inc. common stock as of June 30, 2025.

Armistice Capital, LLC and its managing member Steven Boyd have disclosed a beneficial ownership of 9.99% of Dermata Therapeutics, Inc.'s common stock as of March 31, 2025, held through Armistice Capital Master Fund Ltd.

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have disclosed a passive 0.4% beneficial ownership stake in Dermata Therapeutics, Inc. through an amended Schedule 13G filing.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a continued 9.99% beneficial ownership stake in Dermata Therapeutics, Inc. as of December 31, 2024.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a passive beneficial ownership of 6.7% in Dermata Therapeutics, Inc., totaling 262,468 common shares.